Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Kymera Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Kymera Therapeutics, Inc.’s stock price such as:

• Kymera Therapeutics, Inc.’s current stock price and volume
• Why Kymera Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for KYMR from analysts
• KYMR’s stock price momentum as measured by its relative strength

About Kymera Therapeutics, Inc. (KYMR)

Before we jump into Kymera Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Want to learn more about Kymera Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Kymera Therapeutics, Inc..

Kymera Therapeutics, Inc.’s Stock Price as of Market Close

As of April 16, 2026, 3:32 PM, CST, Kymera Therapeutics, Inc.’s stock price was $85.330.

Kymera Therapeutics, Inc. is down 4.12% from its previous closing price of $89.000.

During the last market session, Kymera Therapeutics, Inc.’s stock traded between $85.180 and $89.230. Currently, there are approximately 89.91 million shares outstanding for Kymera Therapeutics, Inc..

Kymera Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Kymera Therapeutics, Inc. Stock Price History

Kymera Therapeutics, Inc.’s (KYMR) price is currently up 2.45% so far this month.

During the month of April, Kymera Therapeutics, Inc.’s stock price has reached a high of $90.150 and a low of $82.280.

Over the last year, Kymera Therapeutics, Inc. has hit prices as high as $103.000 and as low as $24.425. Year to date, Kymera Therapeutics, Inc.’s stock is up 9.66%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Kymera Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 15, 2026, there was 1 analyst who downgraded Kymera Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Kymera Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Kymera Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Kymera Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Kymera Therapeutics, Inc. (KYMR) by visiting AAII Stock Evaluator.

Relative Price Strength of Kymera Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 15, 2026, Kymera Therapeutics, Inc. has a weighted four-quarter relative price strength of 26.49%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Kymera Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Kymera Therapeutics, Inc. Stock Price: Bottom Line

As of April 16, 2026, Kymera Therapeutics, Inc.’s stock price is $85.330, which is down 4.12% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Kymera Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.